CORRIGENDUM TO PUBLIC ANNOUNCEMENT
TO THE EQUITY SHAREHOLDERS OF

ZENOTECH LABORATORIES LIMITED

Regd. Office: 8-2-120/112/88-89, Park View Estate, 4th Floor, Road No. 2, Banjara Hills, Hyderabad -500034

This announcement ("Corrigendum to the Public Announcement") is in continuation of and should be read in conjunction with the Public Announcement dated October 5, 2007 (the "PA") and is being issued by Rabo India Securities Private Limited (the "Manager to the Offer") for and on behalf of Ranbaxy Laboratories Limited ("RLL" or the "Acquirer") to the equity shareholders of Zenotech Laboratories Limited ("ZLL" or the "Target Company") pursuant to and in compliance with, amongst others, regulations 10 and 12 of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 1997, and subsequent amendments thereof (the "Regulations").

Shareholders are requested to kindly note the following:

a) In terms of Regulation 18(1) of the Regulations, the draft Letter of Offer has been submitted to the Securities and Exchange Board of India (SEBI) on October 19, 2007. The original schedule of activity as disclosed in the PA is delayed and a public announcement containing the revised schedule of activity for the Offer will be announced in due course. This public announcement shall appear in the same newspapers in which the PA had appeared.

b) Pursuant to Escrow Agreement dated November 5, 2007 entered amongst RLL, Dr. Jayaram Chigurupati and his associates (Promoters of the Target Company) (hereinafter referred as the "Promoters") and The Hongkong and Shanghai Banking Corporation Limited and Share Purchase Agreement dated October 3, 2007, 78,78,906 Equity Shares of the Target Company together with corresponding purchase consideration have been placed under Escrow Arrangement with HSBC. Rights of the shareholders in respect of aforesaid shares i.e. dividend, voting etc. shall remain with the Promoters until all the requirements under the Regulations and above-mentioned Share Purchase Agreement have been complied with.

c) Pursuant to the approval of the shareholders of the Target Company in the Annual General Meeting held on November 8, 2007, 54,89,536 Equity Shares at a price of Rs.160/- per share (including premium of Rs.150/- per share) for cash (being 16% of the equity share capital of the Target Company as increased by the above-mentioned preferential issue) were allotted to RLL on November 23, 2007.

Terms used but not defined in this Corrigendum to the PA shall have the same meaning as assigned in the PA. This Corrigendum to the PA is also expected to be available on SEBI's website at http://www.sebi.gov.in. All other terms and conditions of the PA remain unchanged. The Board of Directors of the Acquirer accepts full responsibility for the information (except that which pertains to the Target Company) contained in this Corrigendum, and also accepts responsibility for the obligations of the Acquirer as laid down in the Regulations.

Issued by the Manager to the Offer
For and on behalf of the Acquirer
Ranbaxy Laboratories Limited
Regd. Office: A-11, Industrial Area Phase-III
SAS Nagar, Mohali, Punjab

Rabo India Securities
A 100% subsidiary of Rabo India Finance

Rabo

Rabo India Securities Private Limited
Forbes Building, 2nd Floor
Charanjit Rai Marg, Fort, Mumbai 400 001
Phone: +91 22 22034567
Fax: + 91 22 22037078
Email: abhinav.agarwal@rabobank.com
Contact Person: Abhinav Agarwal

Date : 28 November, 2007
Place : Mumbai, India.